Richard Mattern represents both public and private companies in a variety of corporate and securities law matters, helping clients achieve goals that support their overall strategic initiatives.
As primary corporate and securities counsel to several NYSE- and Nasdaq-listed companies, he has represented clients in transactions ranging from $10 million to $1.4 billion as well as securities offerings ranging from $4 million to $6 billion. He also counsels private companies on capital raising, mergers and acquisitions, and other corporate matters related to their business objectives.
Richard works within a range of industries, with a particular focus in medical device, real estate investment trust (REIT) and manufacturing. His practice includes:
Prior to joining Bass, Berry & Sims, Richard was a shareholder in the Memphis office of Baker, Donelson, Bearman, Caldwell & Berkowitz P.C.
National Association of Real Estate Investment Trusts (NAREIT)
Tennessee Bar Association
American Bar Association — Business Law Section, Committee on Mergers & Acquisitions
American Health Law Association (AHLA)
Junior Achievement — Board of Directors (2015-2019)
The Children’s Museum of Memphis — Board of Directors (2017-2019)
Representation of Prodigo Solutions, Inc., a supply chain and data enablement technology company, in its sale to Global Healthcare Exchange, a healthcare business and data automation company. Terms of the transaction were not disclosed.
Representation of Strategic Storage Growth Trust II, Inc., a private REIT sponsored by an indirect subsidiary of SmartStop, in its sale to SmartStop Self Storage REIT, Inc., a self-managed and fully-integrated self storage company, for approximately $280 million.
Representation of National Guard Products, Inc., a family-owned and full service supplier of aluminum extrusions company, in its acquisition of Anemostat Door Products, Inc, the largest manufacturer of metal vision frames and door louvers in North America. Terms of the transaction were not disclosed.
Representation of Blue Fin Group, a full-service professional management consulting firm delivering research, strategy, and implementation services to help manufacturers optimize access, in its sale to IntegriChain, a comprehensive data and business process platform for Life Sciences market access. Terms of the transaction were not disclosed.
Representation of NN, Inc. (NASDAQ: NNBR) in a new financing with J.P. Morgan, funds managed by Oaktree Capital Management, L.P., and investment funds managed by Morgan Stanley Tactical Value providing a $50 million asset-based credit line (ABL), a 5.5-year $150 million term loan, and a $65 million preferred stock issuance, respectively. Proceeds from the transaction will be used to repay the current principal balance of $70 million on its term loans due in 2022, to redeem its current $100 million outstanding preferred stock, prior to the increase in redemption premium at March 31, 2021, and pay off its fixed interest rate swap of $14 million. The transaction enables the company to strengthen its balance sheet by extending its capital structure’s maturity at an attractive blended cost of capital, allowing the company financial flexibility to continue its current business transformation efforts.
Representation of ClearPoint Neuro, Inc. in its public offering of 2,127,660 shares with proceeds of $46,800,000.
Representation of ClearPoint Neuro, Inc. in its public offering of 2,127,660 shares with proceeds of $46,800,000. B. Riley Securities acted as book-running manager and Lake Street Capital Markets, LLC acted as co-manager for the offering.
We represented ClearPoint Neuro, Inc. (f/k/a MRI Interventions, Inc.), a global therapy-enabling platform company providing navigation and delivery to the brain, in its $17.5 million strategic investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management, with $10.0 million of notes funded by PTC and $7.5 million of notes funded by Petrichor. With the net proceeds from the sale of the notes to PTC and Petrichor, the ClearPoint Neuro intends to repay in full its existing secured indebtedness, and to fund product commercialization, internal research and development, and general corporate requirements. Additionally, we advised ClearPoint Neuro in the draw of $7.5 million additional proceeds from Petrichor in December 2020. ClearPoint Neuro intends to use net proceeds to continue funding global product commercialization, external strategic portfolio partnerships, and internal research and development efforts.
The M&A Advisor — Emerging Leader, Legal Advisor Category (2018)
Best Lawyers® — Memphis Securities/Capital Markets Law “Lawyer of the Year” (2023, 2020)
The Best Lawyers in America© — Securities/Capital Markets Law; Securities Regulation (2019-2023)
Memphis Business Journal “Best of the Bar” — Private Firm, Large (2019 finalist)